It’s the part of coronavirus that helps the virus get into your cells – and also the target of the leading vaccines.
Academic rigor, journalistic flair
Articles on Spike protein
Displaying 21 - 32 of 32 articles
New research shows why the N protein might be a good target.
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There’s a targeted subunit protein vaccine, an mRNA vaccine, and a needle-free DNA vaccine. Here’s what that all means.
The SARS-CoV-2 virus usually infects the body via the ACE2 protein. But there is another entry point that allows the virus to infect the nervous system and block pain perception.
The Australian government is working with two major pharmaceutical companies to facilitate the local production and supply of two different COVID-19 vaccines – if they’re proven to be effective.
As grim as things are with the pandemic raging in the US and the mounting death toll, there are many reasons to be optimistic there will be a vaccine by early next year.
If you have had COVID-19 already, are you protected from another bout of the illness? And is the presence of antibodies in your blood a guarantee of immunity?
Traditional vaccines can take years to create. Rather than immunizing people with viral proteins, the new approach gives the molecular instructions that allows the body to make its own vaccine.
US researchers have revealed the molecular ‘key’ that allows the 2019-nCoV virus to gain access to our cells. And they found it is many times more tenacious than the previous SARS virus.
Top contributors
-
Professor of Medicine, University of Virginia
-
Instructor of Human Immunology, Emory University
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Assistant Professor/Canada Research Chair in emerging viruses, University of Manitoba
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Clinical Research Fellow in Viral Immunology and Veterinary Surgeon, University of Cambridge
-
Associate Professor of Biology, Rochester Institute of Technology
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor of Pediatrics, Vanderbilt University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Senior Lecturer; MD, Victoria University
-
Postdoctoral Scientist, South Australian Health & Medical Research Institute
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Lecturer in Virology, Queen's University Belfast
